Customized quality controls for analytical assays
US-9354144-B2 · May 31, 2016 · US
US9909959B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9909959-B2 |
| Application number | US-201615296901-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 18, 2016 |
| Priority date | Sep 20, 2011 |
| Publication date | Mar 6, 2018 |
| Grant date | Mar 6, 2018 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Solid beads each containing a selected quantity of analyte are combined and a liquid base matrix that contains attributes of a biological fluid that is to be assayed, together constitute a kit from which a laboratory technician can, at the point of use, prepare a liquid control for a particular analyte, and preferably a series of such controls at different levels of the same analyte customized for a particular assay.
Opening claim text (preview).
What is claimed is: 1. A method for determining linearity of an assay response, said method comprising: dissolving one or more solid water-soluble beads in three or more aliquots of an aqueous liquid matrix to prepare three or more liquid solutions each having a different analyte level, wherein the water-soluble beads comprise at least one analyte, a bulking agent, a salt, and a buffer, and said aqueous liquid matrix comprising a salt and a buffer at a pH of from about 4.0 to about 9.0, performing the assay with the three or more liquid solutions to generate an assay response for the analyte in each of the three or more liquid solutions; and determining whether assay responses are linear within a range of analyte concentrations spanned by three or more liquid solutions, thereby determining linearity of an assay response. 2. The method of claim 1 , wherein the water-soluble beads are prepared by lyophilization of an aqueous solution ranging in volume from about 5 μL to about 1,000 μL. 3. The method of claim 1 , wherein dissolving comprises dissolving a plurality of quantities of one or more solid water soluble beads in separate aliquots and the aliquots have equal volumes of the aqueous liquid matrix. 4. The method of claim 1 , wherein dissolving comprises dissolving the same quantity of beads in separate aliquots, and the aliquots have different volumes of the aqueous liquid matrix. 5. The method of claim 1 , wherein the range of analyte concentrations includes concentrations above, below or equal to a known medical decision point concentration for the analyte. 6. The method of claim 1 , wherein at least one of said solid water-soluble beads consists essentially of at least one said analyte, said bulking agent, said salt, and a buffer. 7. The method of claim 1 , wherein said aqueous liquid matrix comprises human or animal source materials from which endogenous species that interfere with the detection of said analytes have been removed. 8. The method of claim 7 , wherein said human or animal source materials comprise a human biological fluid. 9. The method of claim 1 , wherein said aqueous liquid matrix further comprises an albumin. 10. The method of claim 9 , wherein said albumin is selected from the group consisting of human serum albumin and bovine serum albumin. 11. The method of claim 1 , wherein said aqueous liquid matrix further comprises a stabilizer selected from the group consisting of a protease inhibitor, a cryoprotectant, a reducing agent, a chelating agent, a crosslinking agent, and a surfactant. 12. The method of claim 1 , wherein said aqueous liquid matrix further comprises an antimicrobial agent selected from the group consisting of sodium azide, ciprofloxacin, chloramphenicol, gentamicin, amikacin, tobramycin, and amphotericin B. 13. The method of claim 1 , wherein said aqueous liquid matrix has a pH of from about 6.2 to about 8.5. 14. The method of claim 1 , wherein said aqueous liquid matrix has an osmolarity of from about 50 to about 1,000 mOsm/kg. 15. The method of claim 1 , wherein each said water-soluble bead is substantially spherical with a diameter of from about 3 mm to about 10 mm.
involving blood or serum control standard · CPC title
Serum albumin, e.g. HSA · CPC title
using penetration of dyes, e.g. fluorescent ink · CPC title
involving dehydrogenase · CPC title
Reference solutions for assays of biological material · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.